Japan approves stem-cell treatment for Parkinson’s in world first
‘I hope this will bring relief to patients not only in Japan but around the world.’
‘I hope this will bring relief to patients not only in Japan but around the world.’
TOKYO (AFP) — Japan has approved ground-breaking stem-cell treatments for Parkinson’s and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients within months.
Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson’s disease treatment that transplants stem cells into a patient’s brain.
Japan’s health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function, media reports said.
The treatments could be on the market and rolled out to patients as early as this summer, reports said, citing the health ministry, becoming the world’s first commercially available medical products using (iPS) cells.
Japanese scientist Shinya Yamanaka won the Nobel Prize in 2012 for his research into iPS, which have the potential to develop into any cell in the body.
“I hope this will bring relief to patients not only in Japan but around the world,” health minister Kenichiro Ueno told a press conference.
“We will promptly carry out all necessary procedures to ensure it reaches all patients without fail.”
In a statement, Sumitomo Pharma said it had obtained “conditional and time-limited approval” for the manufacture and marketing of Amchepry under a system which is reportedly designed to get these products to patients as quickly as possible.
The approval is a kind of “provisional license,” the Asahi newspaper said, after the safety and efficacy of the treatment was judged based on data from fewer patients than in ordinary clinical trials for drugs.
